![]() Metastatic Cancer Drugs Market Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Therapy Type (Chemotherapy, Immunotherapy, Hormone Therapy, Targeted Therapy, Others), By Type of Cancer (Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Colorectal Cancer, Others), By End-User (Hospitals & Clinics, Ambulatory Centers, Other), By Region & Competition, 2020-2030F
Global Metastatic Cancer Drugs Market was valued at USD 78.75 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.35% through 2030. The Global Me... もっと見る
SummaryGlobal Metastatic Cancer Drugs Market was valued at USD 78.75 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.35% through 2030. The Global Metastatic Cancer Drugs Market is a vital and rapidly evolving sector within the pharmaceutical industry, dedicated to developing advanced therapies for cancers that have spread beyond their original site. These drugs are designed to slow tumor progression, manage symptoms, and enhance patients’ quality of life.Despite significant advancements, the market continues to face key challenges, including high treatment costs and limited progress in certain cancer types. For instance, pancreatic cancer remains highly lethal, with standard treatments such as Folfirinox offering only limited efficacy. However, strong growth prospects remain, driven by rising cancer prevalence, continuous innovations in therapy, and strategic industry collaborations. To ensure sustained market expansion, addressing issues related to treatment affordability and effectiveness, particularly for hard-to-treat cancers, will be essential. Key Market Drivers The Rising Prevalence Of Metastatic Cancer The rising prevalence of metastatic cancer is a significant market driver in the Global Metastatic Cancer Drugs Market. This phenomenon is multifaceted and can be attributed to several interconnected reasons, all of which have a substantial impact on the demand for metastatic cancer drugs. One of the primary factors contributing to the increasing prevalence of metastatic cancer is the global demographic shift toward an aging population. As people age, their risk of developing cancer, including metastatic cancer, increases. This is because the incidence of cancer tends to rise with age, and as a result, there is a growing pool of potential patients requiring cancer treatment. Modern lifestyle choices have also played a pivotal role in the rising incidence of metastatic cancer. Factors such as poor diet, lack of physical activity, smoking, and excessive alcohol consumption are known risk factors for various types of cancer, including those that can metastasize. As these unhealthy habits become more prevalent in society, the occurrence of cancer cases, including metastatic ones, continues to rise. Environmental factors, including exposure to carcinogens and pollutants, have been linked to an increased risk of cancer. Industrialization, urbanization, and the expansion of certain industries have led to greater exposure to harmful substances, contributing to the incidence of metastatic cancer in some regions. Key Market Challenges Drug Development Costs and Time Constraints Developing metastatic cancer drugs is a resource-intensive and time-consuming process. Clinical trials alone can take several years and cost billions of dollars. The need for extensive research, preclinical studies, regulatory approvals, and post-marketing surveillance significantly adds to the expenses and timelines. Additionally, the high attrition rate of experimental drugs during clinical trials further compounds the costs and extends development timelines. Key Market Trends Immunotherapy Dominance Immunotherapy has emerged as a dominant trend in the treatment of metastatic cancer due to its remarkable efficacy and potential for long-lasting responses. Key factors contributing to this trend include: Immunotherapies, such as immune checkpoint inhibitors (e.g., PD-1 and PD-L1 inhibitors) and CAR-T cell therapies, have demonstrated unprecedented success in treating certain metastatic cancers. Patients who had limited treatment options in the past are now experiencing durable responses and improved survival rates. Immunotherapy can be personalized based on a patient's immune profile and tumor characteristics. This tailoring of treatment enhances its effectiveness and minimizes adverse effects, making it an attractive option. Researchers are exploring combinations of immunotherapies with other treatment modalities, such as targeted therapies and chemotherapy, to enhance response rates and overcome resistance. Key Market Players • Bristol-Myers Squibb Company • Merck & Co., Inc. • AstraZeneca Plc • Novartis AG • Eli Lilly & Co. • Pfizer Inc. • F. Hoffmann-La Roche Ltd. • Johnson & Johnson • Amgen Inc. • Sanofi SA Report Scope: In this report, the Global Metastatic Cancer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: • Metastatic Cancer Drugs Market, By Therapy Type: o Chemotherapy o Immunotherapy o Hormone Therapy o Targeted Therapy o Others • Metastatic Cancer Drugs Market, By Type of Cancer: o Breast Cancer o Lung Cancer o Prostate Cancer o Melanoma o Colorectal Cancer o Others • Metastatic Cancer Drugs Market, By End User: o Hospital & Clinics o Ambulatory Centers o Others • Metastatic Cancer Drugs Market, By Region: o North America § United States § Canada § Mexico o Europe § France § United Kingdom § Italy § Germany § Spain o Asia-Pacific § China § India § Japan § Australia § South Korea o South America § Brazil § Argentina § Colombia o Middle East & Africa § South Africa § Saudi Arabia § UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the Global Metastatic Cancer Drugs Market. Available Customizations: Global Metastatic Cancer Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: Company Information • Detailed analysis and profiling of additional market players (up to five). Table of Contents1. Product Overview1.1. Market Definition 1.2. Scope of the Market 1.2.1. Markets Covered 1.2.2. Years Considered for Study 1.2.3. Key Market Segmentations 2. Research Methodology 2.1. Objective of the Study 2.2. Baseline Methodology 2.3. Key Industry Partners 2.4. Major Association and Secondary Sources 2.5. Forecasting Methodology 2.6. Data Triangulation & Validation 2.7. Assumptions and Limitations 3. Executive Summary 3.1. Overview of the Market 3.2. Overview of Key Market Segmentations 3.3. Overview of Key Market Players 3.4. Overview of Key Regions/Countries 3.5. Overview of Market Drivers, Challenges, Trends 4. Voice of Customer 5. Metastatic Cancer Drugs Market Outlook 5.1. Market Size & Forecast 5.1.1. By Value 5.2. Market Share & Forecast 5.2.1. By Therapy Type (Chemotherapy, Immunotherapy, Hormone Therapy, Targeted Therapy, Others) 5.2.2. By Type of Cancer (Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Colorectal Cancer, Others) 5.2.3. By End-User (Hospitals & Clinics, Ambulatory Centers, Other) 5.2.4. By Region 5.2.5. By Company (2024) 5.3. Market Map 6. North America Metastatic Cancer Drugs Market Outlook 6.1. Market Size & Forecast 6.1.1. By Value 6.2. Market Share & Forecast 6.2.1. By Therapy Type 6.2.2. By Type of Cancer 6.2.3. By End User 6.2.4. By Country 6.3. North America: Country Analysis 6.3.1. United States Metastatic Cancer Drugs Market Outlook 6.3.1.1. Market Size & Forecast 6.3.1.1.1. By Value 6.3.1.2. Market Share & Forecast 6.3.1.2.1. By Therapy Type 6.3.1.2.2. By Type of Cancer 6.3.1.2.3. By End User 6.3.2. Canada Metastatic Cancer Drugs Market Outlook 6.3.2.1. Market Size & Forecast 6.3.2.1.1. By Value 6.3.2.2. Market Share & Forecast 6.3.2.2.1. By Therapy Type 6.3.2.2.2. By Type of Cancer 6.3.2.2.3. By End User 6.3.3. Mexico Metastatic Cancer Drugs Market Outlook 6.3.3.1. Market Size & Forecast 6.3.3.1.1. By Value 6.3.3.2. Market Share & Forecast 6.3.3.2.1. By Therapy Type 6.3.3.2.2. By Type of Cancer 6.3.3.2.3. By End User 7. Europe Metastatic Cancer Drugs Market Outlook 7.1. Market Size & Forecast 7.1.1. By Value 7.2. Market Share & Forecast 7.2.1. By Therapy Type 7.2.2. By Type of Cancer 7.2.3. By End User 7.2.4. By Country 7.3. Europe: Country Analysis 7.3.1. Germany Metastatic Cancer Drugs Market Outlook 7.3.1.1. Market Size & Forecast 7.3.1.1.1. By Value 7.3.1.2. Market Share & Forecast 7.3.1.2.1. By Therapy Type 7.3.1.2.2. By Type of Cancer 7.3.1.2.3. By End User 7.3.2. United Kingdom Metastatic Cancer Drugs Market Outlook 7.3.2.1. Market Size & Forecast 7.3.2.1.1. By Value 7.3.2.2. Market Share & Forecast 7.3.2.2.1. By Therapy Type 7.3.2.2.2. By Type of Cancer 7.3.2.2.3. By End User 7.3.3. Italy Metastatic Cancer Drugs Market Outlook 7.3.3.1. Market Size & Forecast 7.3.3.1.1. By Value 7.3.3.2. Market Share & Forecast 7.3.3.2.1. By Therapy Type 7.3.3.2.2. By Type of Cancer 7.3.3.2.3. By End User 7.3.4. France Metastatic Cancer Drugs Market Outlook 7.3.4.1. Market Size & Forecast 7.3.4.1.1. By Value 7.3.4.2. Market Share & Forecast 7.3.4.2.1. By Therapy Type 7.3.4.2.2. By Type of Cancer 7.3.4.2.3. By End User 7.3.5. Spain Metastatic Cancer Drugs Market Outlook 7.3.5.1. Market Size & Forecast 7.3.5.1.1. By Value 7.3.5.2. Market Share & Forecast 7.3.5.2.1. By Therapy Type 7.3.5.2.2. By Type of Cancer 7.3.5.2.3. By End User 8. Asia-Pacific Metastatic Cancer Drugs Market Outlook 8.1. Market Size & Forecast 8.1.1. By Value 8.2. Market Share & Forecast 8.2.1. By Therapy Type 8.2.2. By Type of Cancer 8.2.3. By End User 8.2.4. By Country 8.3. Asia-Pacific: Country Analysis 8.3.1. China Metastatic Cancer Drugs Market Outlook 8.3.1.1. Market Size & Forecast 8.3.1.1.1. By Value 8.3.1.2. Market Share & Forecast 8.3.1.2.1. By Therapy Type 8.3.1.2.2. By Type of Cancer 8.3.1.2.3. By End User 8.3.2. India Metastatic Cancer Drugs Market Outlook 8.3.2.1. Market Size & Forecast 8.3.2.1.1. By Value 8.3.2.2. Market Share & Forecast 8.3.2.2.1. By Therapy Type 8.3.2.2.2. By Type of Cancer 8.3.2.2.3. By End User 8.3.3. Japan Metastatic Cancer Drugs Market Outlook 8.3.3.1. Market Size & Forecast 8.3.3.1.1. By Value 8.3.3.2. Market Share & Forecast 8.3.3.2.1. By Therapy Type 8.3.3.2.2. By Type of Cancer 8.3.3.2.3. By End User 8.3.4. South Korea Metastatic Cancer Drugs Market Outlook 8.3.4.1. Market Size & Forecast 8.3.4.1.1. By Value 8.3.4.2. Market Share & Forecast 8.3.4.2.1. By Therapy Type 8.3.4.2.2. By Type of Cancer 8.3.4.2.3. By End User 8.3.5. Australia Metastatic Cancer Drugs Market Outlook 8.3.5.1. Market Size & Forecast 8.3.5.1.1. By Value 8.3.5.2. Market Share & Forecast 8.3.5.2.1. By Therapy Type 8.3.5.2.2. By Type of Cancer 8.3.5.2.3. By End User 9. South America Metastatic Cancer Drugs Market Outlook 9.1. Market Size & Forecast 9.1.1. By Value 9.2. Market Share & Forecast 9.2.1. By Therapy Type 9.2.2. By Type of Cancer 9.2.3. By End User 9.2.4. By Country 9.3. South America: Country Analysis 9.3.1. Brazil Metastatic Cancer Drugs Market Outlook 9.3.1.1. Market Size & Forecast 9.3.1.1.1. By Value 9.3.1.2. Market Share & Forecast 9.3.1.2.1. By Therapy Type 9.3.1.2.2. By Type of Cancer 9.3.1.2.3. By End User 9.3.2. Argentina Metastatic Cancer Drugs Market Outlook 9.3.2.1. Market Size & Forecast 9.3.2.1.1. By Value 9.3.2.2. Market Share & Forecast 9.3.2.2.1. By Therapy Type 9.3.2.2.2. By Type of Cancer 9.3.2.2.3. By End User 9.3.3. Colombia Metastatic Cancer Drugs Market Outlook 9.3.3.1. Market Size & Forecast 9.3.3.1.1. By Value 9.3.3.2. Market Share & Forecast 9.3.3.2.1. By Therapy Type 9.3.3.2.2. By Type of Cancer 9.3.3.2.3. By End User 10. Middle East and Africa Metastatic Cancer Drugs Market Outlook 10.1. Market Size & Forecast 10.1.1. By Value 10.2. Market Share & Forecast 10.2.1. By Therapy Type 10.2.2. By Type of Cancer 10.2.3. By End User 10.2.4. By Country 10.3. MEA: Country Analysis 10.3.1. South Africa Metastatic Cancer Drugs Market Outlook 10.3.1.1. Market Size & Forecast 10.3.1.1.1. By Value 10.3.1.2. Market Share & Forecast 10.3.1.2.1. By Therapy Type 10.3.1.2.2. By Type of Cancer 10.3.1.2.3. By End User 10.3.2. Saudi Arabia Metastatic Cancer Drugs Market Outlook 10.3.2.1. Market Size & Forecast 10.3.2.1.1. By Value 10.3.2.2. Market Share & Forecast 10.3.2.2.1. By Therapy Type 10.3.2.2.2. By Type of Cancer 10.3.2.2.3. By End User 10.3.3. UAE Metastatic Cancer Drugs Market Outlook 10.3.3.1. Market Size & Forecast 10.3.3.1.1. By Value 10.3.3.2. Market Share & Forecast 10.3.3.2.1. By Therapy Type 10.3.3.2.2. By Type of Cancer 10.3.3.2.3. By End User 11. Market Dynamics 11.1. Drivers 11.2. Challenges 12. Market Trends & Developments 12.1. Recent Developments 12.2. Product Launches 12.3. Mergers & Acquisitions 13. Global Metastatic Cancer Drugs Market: SWOT Analysis 14. Competitive Landscape 14.1. Bristol-Myers Squibb Company 14.1.1. Business Overview 14.1.2. Product & Service Offerings 14.1.3. Recent Developments 14.1.4. Financials (If Listed) 14.1.5. Key Personnel 14.1.6. SWOT Analysis 14.2. Merck & Co., Inc. 14.3. AstraZeneca Plc 14.4. Novartis AG 14.5. Eli Lilly & Co. 14.6. Pfizer Inc. 14.7. F. Hoffmann-La Roche Ltd. 14.8. Johnson & Johnson 14.9. Amgen Inc. 14.10.Sanofi SA. 15. Strategic Recommendations 16. About Us & Disclaimer
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポート
TechSci Research社のヘルスケア分野での最新刊レポート
本レポートと同じKEY WORD(cancer)の最新刊レポート
よくあるご質問TechSci Research社はどのような調査会社ですか?テックサイリサーチ(TechSci Research)は、カナダ、英国、インドに拠点を持ち、化学、IT、環境、消費財と小売、自動車、エネルギーと発電の市場など、多様な産業や地域を対象とした調査・出版活... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|